The Role of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) from Ganoderma lucidum Mycelia Extract on Lipid Profile and Anthropometry in Patients with Cardiometabolic Syndrome

Cardiometabolic syndrome is one of the global health problem. The factor that contributes to the occurrence and severity of cardiometabolic syndrome is central obesity. β-1,3/1,6-D-Glucan (Polysaccharides Peptide) from Ganoderma lucidum (GLPP) is known as a lipid-lowering agent. The study design was double-blinded study experiment with randomized control trial and the sample was taken by purposive sampling with 62 patients with Cardiometabolic Syndrome. SPSS 23.0 software was used to analyze data. Pre- and post-treatment analysis total cholesterol levels showed insignificant deflection in both control (p = 0.068) and GLPP group (p = 0.063). HDL-C levels showed significant deflection both in control (paired t-test, p = 0.000) and GLPP group (p = 0.000). The results for LDL-C levels were insignificant deflection in control group (p=0.216) but significant in the GLPP group (p=0.003). There was an elevation in triglyceride levels, but insignificant in control group (p=0.068) and significant in the GLPP group (p=0.003). This study reports the decreased of BMI and waist circumference in both control groups significantly, p=0.001 for BMI and p=0.002 for waist circumference. Meanwhile, the GLPP group showed an insignificant increase in BMI (p=0.361) but significant in waist circumference (p=0.001). This study result supports that β-1,3/1,6-D-Glucan can reduce the risk of cardiometabolic syndrome by a significant reduction of LDL-C and waist circumference in the GLPP group through influence on lipid metabolism, glycometabolism improvement, modification in the digestive system, and fat burners.